Table 5.

Overall survival due to HRD status in patients with resected pancreatic cancer treated with platinum-based chemotherapy

Study	HRD		Non-HRD		P value
	n	Median OS (months)	n	Median OS (months)
Pishvaian et al 29	49	52.2	220	36	0.1
Golan et al 20	10	43.8	7	44.4	0.775
Blair et al 19	10	31	ND	ND
Yurgelun et al 18	5	20.9	ND	ND
Total	74	46.1	227	36.3

HRD, homologous recombination deficiency; n, number of patients; ND, no data provided.